Based on the Durect Corporation stock forecast from 1 analysts, the average analyst target price for Durect Corporation is USD 5.00 over the next 12 months. Durect Corporation’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Durect Corporation is Very Bearish, which is based on 0 positive signals and 8 negative signals. At the last closing, Durect Corporation’s stock price was USD 0.75. Durect Corporation’s stock price has changed by -4.32% over the past week, -8.48% over the past month and -8.67% over the last year.
No recent analyst target price found for Durect Corporation
No recent average analyst rating found for Durect Corporation
Company Overview Durect Corporation
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Read Less
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in li...Read More
Frequently Asked Questions About Durect Corporation (DRRX) Stock
Based on ratings from 1 analysts Durect Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on DRRX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for DRRX is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on DRRX's stock to indicate if its overvalued.
The last closing price of DRRX's stock was USD 0.75.
The most recent market capitalization for DRRX is USD 0.03B.
Based on targets from 1 analysts, the average taret price for DRRX is projected at USD 5.00 over the next 12 months.
This means that DRRX's stock price may go up by +567.56% over the next 12 months.
We can't find any ETFs which contains Durect Corporation's stock.
As per our most recent records Durect Corporation has 46 Employees.
Durect Corporation's registered address is 10240 Bubb Road, Cupertino, CA, United States, 95014-4166.
You can get more information about it from Durect Corporation's website at https://www.durect.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Durect Corporation (DRRX) Stock
Based on ratings from 1 analysts Durect Corporation's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on DRRX's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for DRRX is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.
Unfortunately we do not have enough data on DRRX's stock to indicate if its overvalued.
The last closing price of DRRX's stock was USD 0.75.
The most recent market capitalization for DRRX is USD 0.03B.
Based on targets from 1 analysts, the average taret price for DRRX is projected at USD 5.00 over the next 12 months.
This means that DRRX's stock price may go up by +567.56% over the next 12 months.
We can't find any ETFs which contains Durect Corporation's stock.
As per our most recent records Durect Corporation has 46 Employees.
Durect Corporation's registered address is 10240 Bubb Road, Cupertino, CA, United States, 95014-4166.
You can get more information about it from Durect Corporation's website at https://www.durect.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DRRX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
